Noven maintains hold rating from Jefferies

Noven Pharmaceuticals, Inc. was maintained by Jefferies & Co., Inc. analyst David Windley at hold with a $17.50 price target. Despite slightly better first-quarter results, Noven did not stir up excitement among investors. Jefferies wants more information around the late-stage pipeline. Shares of the Miami pharmaceutical company were up 6 cents, or 0.32%, at $18.55 on volume of 133,302 shares versus the three-month running average of 191,465 shares. (Nasdaq: NOVN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.